Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | AKT1 | P31749 | 1/20 | 0.45 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.45 |
| ▸ | WNT3A | P56704 | 2/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 2/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.42 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30096834 | 1.00 | LMNA (0.55) | LMNAGAAMAOBAKT1CTNNB1 | |
| SCHEMBL19863264 | 0.82 | LMNA (0.56) | LMNAGAAMAOBCTNNB1WNT3A | |
| SCHEMBL28365387 | 0.81 | LMNA (0.51) | LMNAGAAMAOBCTNNB1WNT3A | |
| SCHEMBL14400198 | 0.81 | AKT1 (0.45) | GAAMAOBAKT1 | |
| Water SCHEMBL3122500 | 0.81 | LMNA (0.55) | LMNAGAAMAOBCTNNB1WNT3A | |
| SCHEMBL714452 | 0.80 | LMNA (0.50) | LMNAGAAMAOBCTNNB1WNT3A | |
| SCHEMBL10519876 | 0.80 | LMNA (0.58) | LMNAGAACTNNB1WNT3ACNR2 | |
| SCHEMBL10347642 | 0.79 | AKT1 (0.61) | LMNAAKT1 | |
| SCHEMBL4882634 | 0.78 | LMNA (0.51) | LMNAGAAMAOBCTNNB1WNT3A | |
| SCHEMBL4882622 | 0.78 | LMNA (0.51) | LMNAGAAMAOBCTNNB1WNT3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3233077-B1 | DOPAMINE D2 RECEPTOR LIGANDS | BROAD INST INC (US) | 2026-05-06 | — | — | EP | disclosed |
| US-12428373-B2 | Dopamine D2 receptor ligands | THE BROAD INSTITUTE, INC. (US) | 2025-09-30 | — | — | US | disclosed |
| US-20240156994-A1 | FLUORINE-CONTAINING COMPOUND AND CONTRAST MEDIUM | TDK CORPORATION (JP) | 2024-05-16 | — | — | US | disclosed |
| CN-116981657-A | Fluorine-containing compound and contrast agent | TDK株式会社 | 2023-10-31 | — | — | CN | disclosed |
| US-20230143552-A1 | DOPAMINE D2 RECEPTOR LIGANDS | THE BROAD INSTITUTE, INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230143552-A1 | DOPAMINE D2 RECEPTOR LIGANDS | THE BROAD INSTITUTE, INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230143552-A1 | DOPAMINE D2 RECEPTOR LIGANDS | THE BROAD INSTITUTE, INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-11498896-B2 | Dopamine D2 receptor ligands | THE BROAD INSTITUTE, INC. (US) | 2022-11-15 | — | — | US | disclosed |
| US-20210147355-A1 | DOPAMINE D2 RECEPTOR LIGANDS | THE BROAD INSTITUTE, INC. (US) | 2021-05-20 | — | — | US | disclosed |
| US-20210147355-A1 | DOPAMINE D2 RECEPTOR LIGANDS | THE BROAD INSTITUTE, INC. (US) | 2021-05-20 | — | — | US | disclosed |
| US-10633336-B2 | Dopamine D2 receptor ligands | THE BROAD INSTITUTE, INC. (US) | 2020-04-28 | — | — | US | disclosed |
| US-10633336-B2 | Dopamine D2 receptor ligands | THE BROAD INSTITUTE, INC. (US) | 2020-04-28 | — | — | US | disclosed |
| US-20180155283-A1 | DOPAMINE D2 RECEPTOR LIGANDS | THE BROAD INSTITUTE, INC. (US) | 2018-06-07 | — | — | US | disclosed |
| US-20180155283-A1 | DOPAMINE D2 RECEPTOR LIGANDS | THE BROAD INSTITUTE, INC. (US) | 2018-06-07 | — | — | US | disclosed |
| US-20180155283-A1 | DOPAMINE D2 RECEPTOR LIGANDS | THE BROAD INSTITUTE, INC. (US) | 2018-06-07 | — | — | US | disclosed |
| EP-3233077-A1 | DOPAMINE D2 RECEPTOR LIGANDS | The Broad Institute Inc. (US) | 2017-10-25 | — | — | EP | disclosed |
| WO-2016100940-A1 | DOPAMINE D2 RECEPTOR LIGANDS | THE BROAD INSTITUTE, INC. (US) | 2016-06-23 | — | — | WO | disclosed |
| WO-2016100940-A1 | DOPAMINE D2 RECEPTOR LIGANDS | THE BROAD INSTITUTE, INC. (US) | 2016-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240156994-A1 | FLUORINE-CONTAINING COMPOUND AND CONTRAST MEDIUM | AFF1, AFF2, AFF4 | LMNA 2100/4885GAA 4305/4885MAOB 772/4885 |
| US-20180155283-A1 | DOPAMINE D2 RECEPTOR LIGANDS | DRD2, DRD3, ARRB1 | LMNA 4642/4885GAA 2661/4885MAOB 574/4885 |
| US-11498896-B2 | Dopamine D2 receptor ligands | DRD2, SLC6A3, NTSR2 | LMNA 4865/4885GAA 2628/4885MAOB 331/4885 |
| US-10633336-B2 | Dopamine D2 receptor ligands | DRD2, ARRB1, DRD3 | LMNA 4825/4885GAA 3339/4885MAOB 711/4885 |
| US-20230143552-A1 | DOPAMINE D2 RECEPTOR LIGANDS | DRD2, SLC6A3, NTSR2 | LMNA 4865/4885GAA 2628/4885MAOB 331/4885 |
| US-20210147355-A1 | DOPAMINE D2 RECEPTOR LIGANDS | DRD2, SLC6A3, NTSR2 | LMNA 4865/4885GAA 2628/4885MAOB 331/4885 |
| US-12428373-B2 | Dopamine D2 receptor ligands | DRD2, SLC6A3, NTSR2 | LMNA 4865/4885GAA 2628/4885MAOB 331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.